Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease

Mazhar Hussain, Muhammad Zafar Majeed Babar, Muhammad Shahbaz Hussain, Lubna Akhtar, Mazhar Hussain, Muhammad Zafar Majeed Babar, Muhammad Shahbaz Hussain, Lubna Akhtar

Abstract

Objective: To determine the effect of Vildagliptin in non-alcoholic, fatty liver disease patients with dyslipidemia.

Methods: A randomized placebo controlled trial was conducted at outpatient clinic of Medical Unit-I of Sheikh Zayed Medical College/Hospital, Rahim Yar Khan, in which fifty eight patients of NAFLD with dyslipidemia were divided in to two, case and control groups. The case group was given tablet Vildagliptin 50mg twice a day for twelve weeks and control group was given placebo in same way. Body weight, body mass index (BMI), lipid profile, liver enzymes and ultrasound finding of fatty liver were assayed before and after treatment.

Results: After 12 weeks treatment of vildagliptin there was significant improvement in following parameters. Body weight and BMI decreased significantly from 88 ± 11 to79 ± 12 kg (p0.036) and 30±4to 27±5 kg/m2 (p 0.005) respectively. Notable reduction in the value of TC, TG and LDL-C (TC:252±24 to 220±20mg/dl (p 0.031); TG: 190±24 to115±22 mg/dl (p 0.005); LDL-C 160±15 to 145±13mg/dl (p 0.004). HDL-C level increased significantly from 29±5to45±4 mg/dl (p 0.001). There was remarkable reduction in aminotransferases level (ALT: 78± 17 to 48±14IU/L (p 0.036). AST: 63.3±13 to41±11IU/L (p 0.002). There was overall 65.5% improvement in fatty liver grading on ultrasound with vildagliptin while non significant effects were seen in placebo group in all of the above parameters.

Conclusion: Vildagliptin exhibited beneficial effects in non-alcoholic fatty liver disease, Non-diabetic patients with dyslipidemia.

Keywords: Body weight; Fatty liver; Grading; Lipid profile; Liver enzymes; Steatosis; Ultrasound; Vildagliptin.

Conflict of interest statement

Declaration of interest: There is no conflict of interest in this study.

References

    1. Ashtaris S, Pourhoseingholi MA, Zali MR. Non alcoholic fatty liver disease in Asia: prevention and planning. World J Hepatol. 2015;7(13):1788–1796. doi:10.4254/wjh.v7.i13.1788.
    1. Milic S, Lulic D, Stimac D. Non alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol. 2014;20(28):9330–9337. doi:10.3748/wjg.v20.i28.9330.
    1. Caldwell S, Argo C. The natural history of Non alcoholic fatty liver disease. Dig Dis Sci. 2010;28:162–168. doi:10.1159/000282081.
    1. Fargion S, Porzio M, Fracanzani AL. Non alcoholic fatty liver disease and vascular disease: state of the art. World J Gastroenterol. 2014;20(37):1306–13324. doi:10.3748/wjg.v20.i37.13306.
    1. Hashimoto E, Tanjgi M, Tokusghige K. Characteristics and diagnosis of NAFLD/NASH. J Gastroenterol Hepatol. 2013;28(4):64–76. doi:10.111/jgh.12271.
    1. Centis E, Marzocchi R, Suppini A, Grave RD, Villanova N, Hickman IJ. The role of life style change in the prevention and treatment of NAFLD. Curr Pharm Des. 2013;19:5270–5279. doi:10.1186/1741-7015-9-70.
    1. Barb D, Portillo-Sanchez P, Cusi K. Pharmacological management of non alcoholic fatty liver disease. Metab Clin Exp. 2016;65:1183–1195. doi:10.16/j.metabol.2016.04.004.
    1. Duez H, Cariou B, Staels B. DPP-4 inhibitors in the treatment of type 2 diabetes. Biochem Pharmacol. 2012;83(7):823–832. doi:10.1016/j.bcp.2011.11.028.
    1. Horie A, Tokuyama Y, Ishizuka T, Suzuki Y, Marumo K, Oshikiri K. The dipeptidyl peptidase-4 inhibitor vildagliptin has the capacity to repair β-cell dysfunction and insulin resistance. Horm Metab Res. 2014;46:814–818. doi:10.1055/s-0034-1382015.
    1. Yilmaz Y, Atug O, Yonal O, Duman D, Ozdogon O, Imeryuz N. Dipeptidyl peptidase-IV inhibitors: therapeutic potential in non alcoholic fatty liver disease. Med Sci Monit. 2009;15(4):1–5.
    1. Takaki A, Kawai D, Yamamoto K. Multiple hits including oxidative stress as pathogenesis and treatment target in non alcoholic steatohepatotis(NASH) Int J Mol Sci. 2013;14:20704–20728. doi:10.3390/ijms.141020704.
    1. Scheen AJ. Cardiovascular effect of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. Post Med J. 2013;125(3):7–20. doi:10.3390/ijms141020704.
    1. Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, Mccullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol. 2009;51(6):1061–1067. doi:10.1016/j.jhep.2009.09.001.
    1. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR. Randomized controlled trial testing the effect of weight loss on non alcoholic steatohepatitis. Hepatology. 2010;51(1):121–129. doi:10.1002/hep.23276.
    1. Wong VW, Chan RS, Wong GL, Cheung BH, Chu WC, Yeung DK. Community based life style modification programme for non alcoholic fatty liver disease: a randomized controlled trials. J Hepatol. 2013;59(3):536–542. doi:10.1016/j.jhep.2013.04.013.
    1. Gomez EV, Perez YM, Berot LC, Gonzalez AT, Oramas BG, Fabian LG. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gasteroenterol. 2015;149(2):367–378. doi:10.1053/j.gastro.2015.04.005.
    1. Ozturk ZA, Kadayifci A. Insulin sensitizers for the treatment of non alcoholic fatty liver disease. World J Hepatol. 2014;6(4):199–206. doi:10.4254/wjh.v6.i4.199.
    1. Li CL, Zhao LJ, Zhou XL, Wu HX, Zhao JJ. Effect of glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non alcoholic fatty liver disease. J Huazhong Univ Sci Technol Med Sci. 2015;35(3):333–336. doi:10.1007/s11596-015-1433-2.
    1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epideminiology of non alcoholic fatty liver disease- meta-analytic assessment of prevalence, incidence and outcomes. Hepatolgy. 2016;64(1):73–84. doi:10.1002/hep.28431.
    1. Qin X, Shen H, Liu M, Yang Q, Zheng S, Sabo M, et al. GLP-1 reduces intestinal lymph flow, triglycerides absorption and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol. 2005;288:943–949. doi:10.1152/ajpqi.00303.2004.
    1. Aller R, Izaola O, Gomez S, Tafur C, Gonzalez G, Berroa E. Effect of silymarin plus vitamin E in patients with non alcoholic fatty liver disease. A randomized clinical pilot study. Eur Rev Med Pharmacol Sci. 2015;19:3118–3124.
    1. Rizzo MR, Marfella R, Barbieri M, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes. Diabetes Care. 2012;35:2076–2082. doi:10.2337/dc12-0199.
    1. Macauley M, Hollingsworth KG, Smith FE, Thelwall PE, Mrabeh AA, Schweizer A. Effect of vildagliptin on hepatic steatosis. J Clin Endocrinol Metab. 2015;100(4):1578–1585. doi:10.1210/jc.2014-3794.
    1. Mookkan J, De S, Shetty P, Kulkarni NM, Devisingh V, Jaji MS. Combination of vildagliptin and rosiglitazone ameliorates non alcoholic fatty liver disease in C57BL/6 mice. Indian J Pharmacol. 2014;46(1):46–50. doi:10.4103/0253-7613.125166.
    1. Shirakawa J, Fujii H, Ohnuma K, Sato K, Ito Y, Kaji M. Diet induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes. 2011;60(4):1246–1257. doi:10.2337/db10-1338.
    1. Yilmaz Y, Yonal O, Deyneli O, Celikel CA, Kalayci C, Duman DG. Effect of sitagliptin in diabetic patients with non alcoholic steatohepatitis. Acta Gastroenterol Belg. 2012;75(2):240–244.
    1. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of non alcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2004;2(12):1107–1115. doi:10.1016/s1542-3565(04)00457-4.
    1. Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE. Pioglitazone versus vitamin E versus placebo for the treatment of non diabetic patients with non alcoholic steatohepatitis: pivens trials design. Contemp Clin Trials. 2009;31(1):86–96. doi:10.1016/j.cct.2008.09.003.
    1. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54:1082–1090. doi:10.1002/hep.24452.
    1. Junker AE, Gluud L, Holst JJ, Knop FK, Vilsholl T. Diabetic and non diabetic patients with non alcoholic fatty liver disease have impaired incretin effect and fasting hyperglucagonaemia. J Intern Med. 2016;279:485–493. doi:10.111/joim.12462.
    1. Firneisz G, Varga T, Lengyel G, Feher J, Ghyczy D, Wichmann B. Serum dipeptidyl peptidase-4 activity in insulin resistant patient of NAFLD: a novel liver disease biomarkers. PLoS ONE. 2010;5(8):12226. doi:10.1371/journal.pone.0012226.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir